MXPA00002654A - Endothelin antagonist and beta receptor blocking agent as combined preparations - Google Patents
Endothelin antagonist and beta receptor blocking agent as combined preparationsInfo
- Publication number
- MXPA00002654A MXPA00002654A MXPA/A/2000/002654A MXPA00002654A MXPA00002654A MX PA00002654 A MXPA00002654 A MX PA00002654A MX PA00002654 A MXPA00002654 A MX PA00002654A MX PA00002654 A MXPA00002654 A MX PA00002654A
- Authority
- MX
- Mexico
- Prior art keywords
- endothelin antagonist
- combination
- beta
- alkyl
- beta receptor
- Prior art date
Links
- 239000002876 beta blocker Substances 0.000 title claims abstract description 11
- 239000002308 endothelin receptor antagonist Substances 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 3
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000005557 antagonist Substances 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 description 13
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 8
- 229950005341 Bucindolol Drugs 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 102000002045 Endothelin Human genes 0.000 description 6
- 108050009340 Endothelin Proteins 0.000 description 6
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 6
- 206010047139 Vasoconstriction Diseases 0.000 description 6
- 230000003042 antagnostic Effects 0.000 description 6
- -1 phenyl radical Chemical class 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000025033 vasoconstriction Effects 0.000 description 6
- 230000035492 administration Effects 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010007554 Cardiac failure Diseases 0.000 description 2
- 206010019280 Heart failure Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000003067 Myocardial Ischemia Diseases 0.000 description 2
- 206010063897 Renal ischaemia Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- BQXQGZPYHWWCEB-UHFFFAOYSA-N 1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2OCC(O)CNC(C)C BQXQGZPYHWWCEB-UHFFFAOYSA-N 0.000 description 1
- 229960002122 Acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N Acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N Alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 229950006323 Angiotensin ii Drugs 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 229960002274 Atenolol Drugs 0.000 description 1
- 229960001035 BOPINDOLOL Drugs 0.000 description 1
- 229960002781 Bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N Bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- UUOJIACWOAYWEZ-UHFFFAOYSA-N Bopindolol Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N Bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 229960001222 Carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N Carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N Carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 208000009863 Chronic Kidney Failure Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000004981 Coronary Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000000718 Duodenal Ulcer Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II dizwitterion Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010061255 Ischaemia Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- CEMAWMOMDPGJMB-UHFFFAOYSA-N Laracor Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- NXWGWUVGUSFQJC-UHFFFAOYSA-N Mepindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-UHFFFAOYSA-N 0.000 description 1
- 229960002704 Metipranolol Drugs 0.000 description 1
- BQIPXWYNLPYNHW-UHFFFAOYSA-N Metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 229960004255 Nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N Nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N Penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N Pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229940093429 Polyethylene Glycol 6000 Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 description 1
- 208000003782 Raynaud Disease Diseases 0.000 description 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 206010038436 Renal failure acute Diseases 0.000 description 1
- 206010038444 Renal failure chronic Diseases 0.000 description 1
- 229960002370 Sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N Sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042316 Subarachnoid haemorrhage Diseases 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- MXFWWQICDIZSOA-UHFFFAOYSA-N Talinolol Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1NC(=O)NC1CCCCC1 MXFWWQICDIZSOA-UHFFFAOYSA-N 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- 230000003276 anti-hypertensive Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- 229960004634 carazolol Drugs 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 229910000460 iron oxide Inorganic materials 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960003134 mepindolol Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003658 talinolol Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
The invention relates to a combination consisting of endothelin-antagonists and beta receptor blocking agents. Said combination is suitable for the treatment of diseases.
Description
PHARMACEUTICAL PREPARATIONS IN COMBINATION
The present invention relates to novel combination pharmaceutical preparations which are suitable for the treatment of vasoconstriction-based conditions and which contain a beta-receptor blocker and an endoletin antagonist. Suitable combination preparations for the treatment of vasoconstriction-based conditions and containing a beta-receptor blocker and an endoletin antagonist have already been described (WO 92/13545). However, the activity of these combinations of active compounds is not satisfactory. Now combinations have been found with improved properties. The present invention offers a combination of an endothelin antagonist of the formula I:
wherein the substituents are as defined below:
R is C1-C4 alkyl, C1-C4 alkoxy; 2 R is C 1 -C 4 alkyl, C 1 -C 4 alkoxy; R is Ci-Cß alkyl which may be substituted by a phenyl radical which in turn may be substituted by one or two C1-C4 alkoxy radicals, Z is oxygen or a single bond, and a beta receptor blocker.
Preferred endothelin antagonists are those compounds of formula I wherein the substituents are as defined below: R 1: C 1 -C 2 alkyl, C 3 -C 2 alkoxy; R 'C 1 -C 2 alkyl, C 1 -C 2 alkoxy; R C 1 -C 2 alkyl which may be substituted by a phenyl radical which in turn may be substituted by one or two C 1 -C 2 alkoxy radicals, Z is oxygen or a single bond. Particularly suitable endothelin antagonists are the compounds:
Suitable beta-receptor blockers are, in particular, acebutolol, alprenolol, atenolol metropolol, bupranolol, penbutolol, propranolol, is olol, bisoprolol, carazolol, talinolol, mepindolol, sotalol, metipranolol, pindolol, carteolol, tetratolol, celipropol, nadolol, oxprenolol and bopindolol In particular, carvedilol and bucindolol can be mentioned. The combination of a β-blocker with an inhibitor of the ET system can be used as a composition for the treatment of diseases that are based on vasoconstriction or are associated with pathological vasoconstriction. Examples are all forms of high blood pressure (including pulmonary hypertension), heart disease, heart failure, renal and myocardial ischemia, acute and chronic renal failure. The diseases that are associated with vasoconstriction or other biological effects of endothelin and / or angiotensin II are, in particular, the control and / or prevention of coronary diseases, cardiovascular diseases such as hypertension, heart failure, ischemia (in heart, brain, gastrointestinal). , liver and / or kidney) or vasospasms. Other examples of diseases that can be treated are renal and myocardial ischaemia, renal failure, dialysis, subarachnoid hemorrhage, Raynaud's syndrome, high portal pressure and high pulmonary pressure and also the treatment of gastric and duodenal ulcers and of staph ulcers where it is involved vasoconstriction. Finally, in patients with asthma, the concentration of endothelin in the bronchial discharge increases. In migraine attacks, increased levels of endothelin are also observed in the blood plasma. The combination can, therefore, also be used in these cases. When the combination according to the invention is administered, there is a significant increase in the antihypertensive properties and the duration of the action in comparison with the individual substances, and this superadditive effect. Accordingly, the dose of the individual active compounds can be reduced considerably. Thus, there is a lower risk of adverse effects during administration. The weight ratio of the β-receptor blocker to the endothelin antagonists is usually in the range from 50: 1 to 1: 500, preferably from 10: 1 to 1: 100 and in particular from 2: 1 to 1: fifty. The combinations according to the invention are generally administered orally, for example, in the form of tablets not covered, plated or covered with sugar, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be carried out rectally, for example in the form of suppositories, or parenterally, for example in the form of solutions for injection. The administration of the active compound can be carried in the form of products containing both active compounds together, such as tablets or capsules or separately as an ad-hoc combination of individual substances that can be administered concurrently or in sequence. To produce uncoated, plated or sugar coated tablets and hard gelatin capsules, a combination according to the invention can be processed with pharmaceutically inert inorganic or organic excipients. - The excipients of these types that can be used for tablets not covered and covered with sugar and hard gelatine capsules are lactose, corn starch, or derivatives thereof, talc, stearic acid or salts thereof. Suitable excipients for soft gelatine capsules are vegetable oils, fatty waxes, semi-solid or liquid polyols. Suitable excipients for producing solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Suitable excipients for injection solutions are water alcohols, polyols, glycerol, vegetable oils. Suitable excipients for suppositories are natural or hydrogenated oils, waxes, fats, semi-liquid or liquid polyols and the like. The pharmaceutical preparations can also contain preservatives, solubilizers, stabilizers. Wetting agents, emulsifiers, sweeteners, colorants, flavorings. Salts to modify the osmotic pressure, buffer solutions, coating agents and / or antioxidants. The unexpected advantageous properties of the compositions according to the invention are demonstrated by the following tests: In a crossover design, the test substance was administered orally as a capsule to chronically instrumented male beagle dogs (approximately 14 kg). The capsule contained nothing (control N = 5), compound A (10 mg / kg N = 10), bucindolol (0.1 mg / kg); N = 5) or the combination bucindolol plus compound A (0.1 + 10 mg / kg / N = 5). Between the individual administrations, a washing phase of at least one week was observed. Systolic and diastolic blood pressure were measured using a Statham Transducer P 23Db, from which the mean arterial blood pressure was calculated. Blood pressure was recorded for 6 hours
2 (MI, Modular Instrumente, USA). Table 1 shows that the blood pressure in the control group and in the group treated with bucindolol does not decrease. A slight reduction in blood pressure can be observed with compound A. The combination of bucindolol with ET antagonist compound A (0.1 + 10 mg / kg) gave rise to a considerable reduction in blood pressure.
Table 1: Development of the mean arterial blood pressure (mmHg, change with respect to the initial value) in normotensive conscious dogs after oral administration of different substances, which are shown as average values.
The following examples illustrate the invention.
Example 1 Plaque tablets of the following composition were prepared:
Compound A 100.0 mg Bucindolol 10.0 mg Lactose anhydrous 30.0 mg Microcrystalline cellulose 30.0 mg Polyvinylpyrrolidone 20.0 mg Magnesium stearate 5.0 mg Polyethylene glycol 6000 0.8 mg Yellow iron oxide 1.2 mg Titanium dioxide 0.3 mg Talc 0.7 mg
Compound A, bucindolol, lactose, gelulose and polyvinylpyrrolidone are wet granulated and dried. The sifted granules are mixed with the magnesium stearate, and the mixture ready to be compressed is compressed into oval tablet cores each weighing 190.0 mg. The cores are then covered with lacquer until the lacquer-coated tablets have reached a final weight of 200 mg.
Example 2 Preparation of hard gelatine capsules of the following composition:
Compound A 100.0 mg Bucindolol 30.0 mg Crystalline lactose 18.0 mg Polyvinylpyrrolidone 15.0 mg Microcrystalline cellulose 17.5 mg Carboxymethyl sodium starch 10.0 mg Talc 9.0 mg Magnesium stearate 3.0 mg The first five components are wet granulated and dried. The granules are mixed with sodium carboxymethyl starch, talc and magnesium stearate, and the mixture is packed into size 1 hard gelatin capsules.
Claims (4)
1. A combination of an endothelin antagonist of the • formula I: 10 in which the substituents are as defined • continued: R is C 1 -C 4 alkyl, C 1 -C 4 alkoxy; 2 R is C 1 -C 4 alkyl, C 1 -C 4 alkoxy; 3 R is alkyl of -Ci-Cs which may be substituted by 15 a phenyl radical which in turn can be substituted by one or two C1-C4 alkoxy radicals, Z is oxygen or a single bond,
2. A pharmaceutical preparation, containing a combination as mentioned in claim 1. 20
3. A process for preparing a pharmaceutical preparation, which consists in making a mixture of a beta-receptor blocker and an endothelin antagonist as mentioned in claim 1 in a pharmaceutical administration form.
4. The use of a combination of a beta-receptor blocker and an endothelin antagonist as recited in claim 1, or of a pharmaceutical preparation containing a beta-blocker receptor and an endothelin antagonist as recited in claim 1, simultaneous, separate or successive use in the treatment of diseases.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19743143.7 | 1997-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00002654A true MXPA00002654A (en) | 2001-05-17 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1212081B2 (en) | Use of ramipril in the prevention of congestive heart failure | |
US20080318982A1 (en) | Pharmaceutical Combination for the Treatment of Luts | |
WO2005070462A2 (en) | Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use | |
AU2003206738A1 (en) | Pharmaceutical compositions comprising valsartan and nep inhibitors | |
HU221202B1 (en) | Synergetic pharmaceutical combination containing a benzolsulfonamid-derivative and cilazapril | |
US20100311756A1 (en) | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof | |
KR20070091049A (en) | Alpha-2-delta ligand to treat lower urinary tract symptoms | |
US6352992B1 (en) | Endothelin antagonist and beta receptor blocking agent as combined preparations | |
CA2013801A1 (en) | Synergistic compositions containing ketanserin | |
EP1441723B1 (en) | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension | |
MXPA00002654A (en) | Endothelin antagonist and beta receptor blocking agent as combined preparations | |
KR100260479B1 (en) | Antihypertensive combinations | |
JPH0148245B2 (en) | ||
JP4525964B2 (en) | Pulmonary hypertension preventive and therapeutic agent | |
EP1115399B1 (en) | Use of a pharmaceutical composition containing, in combination, an antagonist of the angiotensin ii at 1? receptors and indomethacin for making a medicine treating chronic glomerulonephritis | |
BE896621A (en) | NEW THERAPEUTIC USE OF PROSTAGLANDIN ANALOGS | |
WO2006002983A1 (en) | Combination of organic compounds | |
JPH08269013A (en) | Pyrazoline derivative, radical scavenger, suppressing agent for brain infarction and that for brain edema | |
WO2001013952A1 (en) | Preventives/remedies for heart failure | |
HU206612B (en) | Process for producing antihypertenzive combinative composition | |
JPH08165239A (en) | Anti-arteriosclerotic agent |